184368-74-9

Basic information

• Product Name: 4(2H)-Pyridinedicarboxylic acid, 3,6-dihydro-, 1-(1,1-diMethylethyl)4-Methyl ester
• Synonyms: 4(2H)-Pyridinedicarboxylic acid, 3,6-dihydro-, 1-(1,1-diMethylethyl)4-Methyl ester;Methyl 1-Boc-1,2,3,6-tetrahydropyridine-4-carboxylate;1-tert-butyl 4-methyl 5,6-dihydropyridine-1,4(2H)-dicarboxylate;1,4(2H)-Pyridinedicarboxylic acid, 3,6-dihydro-, 1-(1,1-dimethylethyl) 4-methyl ester
• CAS NO: 184368-74-9
• Molecular Formula: C₁₂H₁₉NO₄
• Molecular Weight: 241.28356
• EINECS: -0
• Mol File: 184368-74-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 315.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.129±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -2.43±0.40(Predicted)
• CAS DataBase Reference: 4(2H)-Pyridinedicarboxylic acid, 3,6-dihydro-, 1-(1,1-diMethylethyl)4-Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4(2H)-Pyridinedicarboxylic acid, 3,6-dihydro-, 1-(1,1-diMethylethyl)4-Methyl ester(184368-74-9)
• EPA Substance Registry System: 4(2H)-Pyridinedicarboxylic acid, 3,6-dihydro-, 1-(1,1-diMethylethyl)4-Methyl ester(184368-74-9)

Safety Data

• Hazardous Substances Data: 184368-74-9(Hazardous Substances Data)

Usage

General Description

The chemical 4(2H)-Pyridinedicarboxylic acid, 3,6-dihydro-, 1-(1,1-diMethylethyl)4-Methyl ester, also known as trimethyl 3,6-dihydro-4-methyl-2(1H)pyridine dicarboxylate, is an organic compound used in the pharmaceutical industry. It is a derivative of pyridine and is commonly used as an intermediate in the synthesis of various pharmaceuticals such as angiotensin receptor antagonists. It is also used as an intermediate in the manufacturing of other organic chemicals and is known for its role as a building block in the pharmaceutical industry. The compound is valued for its ability to participate in numerous chemical reactions and functional groups, making it a versatile and valuable chemical in drug development and other industrial applications.

Upstream product

• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 50893-53-3 carbonochloridic acid 1-chloro-ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 80845-58-5 methyl 1-benzyl-1,2,3,6-tetrahydropyridine-4-carboxylate 
• 70684-84-3 1-[(tert-butoxy)carbonyl]-1,2,3,6-tetrahydropyridine-4-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 792136-23-3 methyl 1,2,3,6-tetrahydro-4-pyridinecarboxylate 
• 94983-57-0 1-benzyl-4-(methoxycarbonyl)pyridin-1-ium 
• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 203663-26-7 t-butyl 4-(hydroxymethyl)-3,6-dihydropyridine-1(2H)-carboxylate 
• 906663-27-2 3-benzylsulfanyl-4-[1-(1-benzylsulfanylmethyl-4-butylcarbamoyl-2-hydroxypentylcarbamoyl)ethylcarbamoyl]piperidine-1-carboxylic acid tert-butyl ester 
• 906663-26-1 (3R,4S)-3-benzylsulfanylpiperidine-1,4-dicarboxylic acid 1-tert-butyl ester 

Relevant articles and documents

Palladium-Catalyzed Visible-Light-Driven Carboxylation of Aryl and Alkenyl Triflates by Using Photoredox Catalysts

A visible-light-driven carboxylation of aryl and alkenyl triflates with CO2 is developed by using a combination of Pd and photoredox catalysts. This reaction proceeds under mild conditions and can be applied to a wide range of substrates including acyclic alkenyl triflates.

Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same

The present invention relates to a novel autotaxin inhibitor compound for preventing and treating disease or symptoms due to an increase in concentration of lysophosphatidic acid or activation of autotaxin. The present invention further relates to a pharmaceutical composition containing the same. The novel compound of the present invention is an autotaxin inhibitor which inhibits production of lysophosphatidic acid, and thus is useful for treating or preventing cardiovascular disease, cancer, metabolic disease, kidney disease, liver disease, inflammatory diseases, nervous disease, respiratory disease, desmoid disease, eye disease, cholestatic symptoms, other types of chronic pruritus or acute, or chronic rejection of transplanted organs.COPYRIGHT KIPO 2017

AROMATIC AMIDES

This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.